Skip to main content

REGULACION DE LOS PROCESOS DE MIELINIZACION Y REMIELINIZACION POR NEUROTRANSMISORES

SAF2016-75292-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

CB1 receptors in NG2 cells mediate cannabinoid-evoked functional myelin regeneration

  • Sánchez De La Torre, Aníbal
  • Ezquerro Herce, Sara
  • Huerga Gómez, Alba
  • Sánchez Martín, Ester
  • Chara, Juan Carlos
  • Matute, Carlos
  • Monory, Krisztina
  • Mato, Susana
  • Lutz, Beat
  • Guzmán Pastor, Manuel
  • Aguado Sánchez, Tania
  • Palazuelos Diego, Javier
Defects in myelin homeostasis have been reported in many neuropathological conditions. Cannabinoid compounds have been shown to efficiently promote myelin regeneration in animal models of demyelination. However, it is still unknown whether this action relies mostly on a cell autonomous effect on oligodendroglial-lineage-NG2 cells. By using conditional genetic mouse models, here we found that cannabinoid CB1 receptors located on NG2 cells are required for oligodendroglial differentiation and myelin regeneration after demyelination. Selective CB1 receptor gene depletion in NG2 cells following toxin-induced demyelination disrupted oligodendrocyte regeneration and functional remyelination and exacerbated axonal damage. These deficits were rescued by pharmacological blockade of the RhoA/ROCK/Cofilin pathway. Conversely, tetrahydrocannabinol administration promoted oligodendrocyte regeneration and functional remyelination in wild-type but not Ng2-CB1-deficient mice. Overall, this study identifies CB1 receptors as essential modulators of remyelination and support the therapeutic potential of cannabinoids for promoting remyelination in neurological disorders.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Clonal NG2-Glia Cell Response in a Mouse Model of Multiple Sclerosis

  • Barriola, Sonsoles
  • Pérez-Cerdá, Fernando
  • Matute, Carlos
  • Bribián, Ana
  • López-Mascaraque, Laura
© 2020 by the authors., NG2-glia, also known as oligodendrocyte precursor cells (OPCs), have the potential to generate new mature oligodendrocytes and thus, to contribute to tissue repair in demyelinating diseases like multiple sclerosis (MS). Once activated in response to brain damage, NG2-glial cells proliferate, and they acquire a reactive phenotype and a heterogeneous appearance. Here, we set out to investigate the distribution and phenotypic diversity of NG2-glia relative to their ontogenic origin, and whether there is a clonal NG2-glial response to lesion in an experimental autoimmune encephalomyelitis (EAE) murine model of MS. As such, we performed in utero electroporation of the genomic lineage tracer, StarTrack, to follow the fate of NG2-glia derived from single progenitors and to evaluate their response to brain damage after EAE induction. We then analyzed the dispersion of the NG2-glia derived clonally from single pallial progenitors in the brain of EAE mice. In addition, we examined several morphological parameters to assess the degree of NG2-glia reactivity in clonally-related cells. Our results reveal the heterogeneity of these progenitors and their cell progeny in a scenario of autoimmune demyelination, revealing the ontogenic phenomena at play in these processes., This research was funded by research Grants from the Fundación Ramón Areces (Ref. CIVP9A5928), MINECO (BFU2016-75207-R), SAF2016-75292-R, CIBERNED and Gobierno Vasco (IT1203-19)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Clemastine induces an impairment in developmental myelination

  • Palma, Ana
  • Chara, Juan Carlos
  • Montilla, Alejandro
  • Otxoa de Amezaga, Amaia
  • Ruíz-Jaén, Francisca
  • Planas, Anna M.
  • Matute, Carlos
  • Pérez-Samartín, Alberto
  • Domercq, María
Abnormalities in myelination are associated to behavioral and cognitive dysfunction in neurodevelopmental psychiatric disorders. Thus, therapies to promote or accelerate myelination could potentially ameliorate symptoms in autism. Clemastine, a histamine H1 antagonist with anticholinergic properties against muscarinic M1 receptor, is the most promising drug with promyelinating properties. Clemastine penetrates the blood brain barrier efficiently and promotes remyelination in different animal models of neurodegeneration including multiple sclerosis, ischemia and Alzheimer’s disease. However, its role in myelination during development is unknown. We showed that clemastine treatment during development increased oligodendrocyte differentiation in both white and gray matter. However, despite the increase in the number of oligodendrocytes, conduction velocity of myelinated fibers of corpus callosum decreased in clemastine treated mice. Confocal and electron microscopy showed a reduction in the number of myelinated axons and nodes of Ranvier and a reduction of myelin thickness in corpus callosum. To understand the mechanisms leading to myelin formation impairment in the presence of an excess of myelinating oligodendrocytes, we focused on microglial cells that also express muscarinic M1 receptors. Importantly, the population of CD11c+ microglia cells, necessary for myelination, as well as the levels of insulin growth factor-1 decrease in clemastine-treated mice. Altogether, these data suggest that clemastine impact on myelin development is more complex than previously thought and could be dependent on microglia-oligodendrocyte crosstalk. Further studies are needed to clarify the role of microglia cells on developmental myelination., This work was supported by Spanish Ministry of Education and Science (SAF 2016-75292- R); Spanish Ministry of Science and Innovation (PID 2019-109724RB-I00); Basque Government (PI-2016-1-0016); the University of the Basque Country (UPV/EHU); and Centro de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED; grant CB06/05/0076). AP has a predoctoral fellowship from the University of the Basque Country (UPV/EHU), AM has a predoctoral fellowship from the Spanish Ministry of Education and Science and AO-de-A has a postdoctoral fellowship from the Basque Government., Peer reviewed